Legal status in the United States
Is ARA-290 legal?
Read at FDA, DEA and WADAPublished by PepVault
ARA-290 (cibinetide) has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA’s class S2.1.5 covers it), as of November 18, 2026.
ARA-290 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved |
| Compounding | Nominated without adequate support (503A category 3) |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned by its class (S2.1.5) |
FDA approval
ARA-290 (cibinetide) has no FDA-approved product: Drugs@FDA lists no application for it.
- Drugs@FDA data (openFDA): applications listing “CIBINETIDE” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
FDA lists cibinetide (ARA-290) in 503A category 3, bulk substances nominated without adequate support, on its list updated May 14, 2026; it is not on FDA’s category 2 page or the 503B bulks list.
The source: “Cibinetide (ARA-290)”
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans it at all times, in and out of competition, by its class: S2.1.5 of the 2026 list bans “innate repair receptor agonists”, and its developer’s trial record on ClinicalTrials.gov describes ARA-290 as a peptide that “activates the innate repair receptor”.
The source: “Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO)”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
- ClinicalTrials.gov record NCT02039687: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis, ClinicalTrials.gov (National Library of Medicine). Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about ARA-290 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is ARA-290 FDA approved?
ARA-290 (cibinetide) has no FDA-approved product: Drugs@FDA lists no application for it.
Is ARA-290 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is ARA-290 banned in sport?
WADA bans it at all times, in and out of competition, by its class: S2.1.5 of the 2026 list bans “innate repair receptor agonists”, and its developer’s trial record on ClinicalTrials.gov describes ARA-290 as a peptide that “activates the innate repair receptor”.
What does FDA say about compounding ARA-290?
FDA lists cibinetide (ARA-290) in 503A category 3, bulk substances nominated without adequate support, on its list updated May 14, 2026; it is not on FDA’s category 2 page or the 503B bulks list.
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.